New Food and Drug Administration funding could provide an opportunity for neurofibromatosis clinical trial applications to be supported. FDA Orphan Products Development Grants support the clinical development of products for use in rare diseases or conditions for which no current therapy exists or when the proposed product would be superior to the existing therapy. This would include neurofibromatosis, and the Children’s Tumor Foundation encourages NF researchers to apply. Phase 1 clinical trials are eligible for grants of up to $200,000 per year for up to 3 years. Phase 2 and 3 clinical trials are eligible for grants up to $400,000 per year for 4 years. Dollar caps represent ALL costs (i.e. direct plus indirect).
Next application deadline is February 2, 2011. Questions: contact Katherine Needleman at Katherine.needleman@fda.hhs.gov or 301-796-8660. To read the request for applications click here.
